Table 3.
Vaccination | Indications | Comment |
---|---|---|
HPV vaccination63 | Through age 26, regardless of prior or current HPV infection status | 3 doses of 4-valent or 9-valent vaccine; 2 doses if age 11–12 |
Hepatitis A virus vaccination3 | No known prior or current infection, or prior vaccination | 2–3 dose series depending on vaccine |
Hepatitis B virus vaccination3 | No known prior or current infection, or prior vaccination | 3-dose series |
Meningococcal vaccination33, 64 | HIV-positive persons above age 2, including HIV-positive MSM | 2-dose series of conjugated vaccine for serotypes A/C/W/Y |
HIV Prophylaxis | Indications | Comment |
Pre-Exposure Prophylaxis67 |
|
Discuss and refer to PrEP providers to consider PrEP initiation, in addition to safer sex counseling to decrease risk of HIV acquisitiona |
Non-Occupational Post-Exposure Prophylaxis72 | Exposure with substantial risk for HIV acquisition within 72 hours from a source known to be HIV-positive; for other exposures with risk, consider on a case-by-case basis | Refer immediately for evaluation and treatment; must initiate nPEP within 72 hours of exposure |
HIV, human immunodeficiency virus; HPV, human papillomavirus; PrEP, pre-exposure prophylaxis; nPEP, non-occupational post-exposure prophylaxis
A national directory of PrEP providers is at www.preplocator.org.71